Caribou Biosciences, Inc. – NASDAQ:CRBU
Founder-led company
Caribou Biosciences stock price today
$1.8
+0.13
+7.78%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
Caribou Biosciences stock price monthly change
-17.33%
month
Caribou Biosciences stock price quarterly change
-17.33%
quarter
Caribou Biosciences stock price yearly change
-71.74%
year
Caribou Biosciences key metrics
Market Cap | 160.27M |
Enterprise value | 247.26M |
P/E | -2.87 |
EV/Sales | 24.33 |
EV/EBITDA | -2.47 |
Price/Sales | 27.35 |
Price/Book | 0.92 |
PEG ratio | -0.12 |
EPS | -1.45 |
Revenue | 33.40M |
EBITDA | -128.99M |
Income | -115.26M |
Revenue Q/Q | -30.63% |
Revenue Y/Y | 127.40% |
Profit margin | -978.65% |
Oper. margin | -1047.34% |
Gross margin | 0% |
EBIT margin | -1047.34% |
EBITDA margin | -386.16% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCaribou Biosciences stock price history
Caribou Biosciences stock forecast
Caribou Biosciences financial statements
| Jun 2023 | 3.75M | -29.51M | -786.13% |
|---|---|---|---|
| Sep 2023 | 23.66M | -10.00M | -42.27% |
| Dec 2023 | 3.55M | -34.50M | -969.79% |
| Mar 2024 | 2.42M | -41.23M | -1697.57% |
| Mar 2024 | 2.42M | -41.23M | -1697.57% |
|---|---|---|---|
| Sep 2025 | 6M | -45.98M | -766.42% |
| Oct 2025 | 4.75M | -56.70M | -1193.84% |
| Dec 2025 | 5.25M | -61.17M | -1165.19% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-07 | -0.38 | -0.12 |
|---|---|---|
| 2024-03-11 | -0.22 | -0.39 |
| 2024-05-07 | -0.39 | -0.46 |
| Jun 2023 | 349647000 | 80.18M | 22.93% |
|---|---|---|---|
| Sep 2023 | 457521000 | 59.25M | 12.95% |
| Dec 2023 | 440968000 | 72.56M | 16.46% |
| Mar 2024 | 406825000 | 63.53M | 15.62% |
| Jun 2023 | -15.18M | 11.06M | 17.57M |
|---|---|---|---|
| Sep 2023 | -28.78M | -68.47M | 135.12M |
| Dec 2023 | -21.37M | -31.47M | -43K |
| Mar 2024 | -37.20M | 22.95M | 12.48M |
Caribou Biosciences alternative data
| Aug 2023 | 137 |
|---|---|
| Sep 2023 | 137 |
| Oct 2023 | 137 |
| Nov 2023 | 137 |
| Dec 2023 | 137 |
| Jan 2024 | 137 |
| Feb 2024 | 137 |
| Mar 2024 | 158 |
| Apr 2024 | 158 |
| May 2024 | 158 |
| Jun 2024 | 158 |
| Jul 2024 | 158 |
Caribou Biosciences other data
34.72%
-32.96%
of CRBU is owned by hedge funds
76
-53
21.11M
-20.09M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2022 | 0 | 43248 |
| Oct 2022 | 0 | 10000 |
| Jan 2023 | 0 | 5627 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KANNER STEVEN officer: Chief Sc.. | Common Stock | 30,577 | $2.69 | $82,252 | ||
Option | KANNER STEVEN officer: Chief Sc.. | Option to purchase Common Stock | 30,577 | $2.69 | $82,252 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Common Stock | 10,000 | $2.96 | $29,600 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Common Stock | 10,000 | $2.96 | $29,600 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Option to purchase Common Stock | 10,000 | $2.96 | $29,600 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Option to purchase Common Stock | 10,000 | $2.96 | $29,600 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Option to purchase Common Stock | 10,000 | $2.96 | $29,600 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Option to purchase Common Stock | 10,000 | $2.96 | $29,600 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Common Stock | 10,000 | $2.96 | $29,600 | ||
Option | HAURWITZ RACHEL E. director, officer.. | Common Stock | 10,000 | $2.96 | $29,600 |
Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value
Caribou Biosciences: Under The Radar With Catalysts Approaching
Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing
Caribou Biosciences: Positive CB-010 Data Leads To First Half 2024 Catalyst
Caribou: Potential To Improve Response Duration With Higher Dose Level
Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability
Caribou Biosciences: Potential To Change CAR-T Landscape
The Correction In Biopharmaceutical Stocks Is Likely Over
Editas: CRISPR Gene Editing Biotech With Promising Future
-
What's the price of Caribou Biosciences stock today?
One share of Caribou Biosciences stock can currently be purchased for approximately $1.8.
-
When is Caribou Biosciences's next earnings date?
Unfortunately, Caribou Biosciences's (CRBU) next earnings date is currently unknown.
-
Does Caribou Biosciences pay dividends?
No, Caribou Biosciences does not pay dividends.
-
How much money does Caribou Biosciences make?
Caribou Biosciences has a market capitalization of 160.27M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 148.91% to 34.48M US dollars. Caribou Biosciences made a loss 102.07M US dollars in net income (profit) last year or -$0.46 on an earnings per share basis.
-
What is Caribou Biosciences's stock symbol?
Caribou Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "CRBU".
-
What is Caribou Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Caribou Biosciences?
Shares of Caribou Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Caribou Biosciences's key executives?
Caribou Biosciences's management team includes the following people:
- Dr. Rachel E. Haurwitz Ph.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 39, pay: $670,220)
- Ms. Barbara G. McClung J.D., Esq. Chief Legal Officer & Corporation Sec.(age: 70, pay: $513,990)
- Dr. Steven B. Kanner Chief Scientific Officer(age: 66, pay: $500,510)
-
Is Caribou Biosciences founder-led company?
Yes, Caribou Biosciences is a company led by its founder Dr. Rachel E. Haurwitz Ph.D..
-
How many employees does Caribou Biosciences have?
As Jul 2024, Caribou Biosciences employs 158 workers.
-
When Caribou Biosciences went public?
Caribou Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 23 Jul 2021.
-
What is Caribou Biosciences's official website?
The official website for Caribou Biosciences is cariboubio.com.
-
Where are Caribou Biosciences's headquarters?
Caribou Biosciences is headquartered at 2929 7th Street, Berkeley, CA.
-
How can i contact Caribou Biosciences?
Caribou Biosciences's mailing address is 2929 7th Street, Berkeley, CA and company can be reached via phone at +51 09826030.
Caribou Biosciences company profile:
Caribou Biosciences, Inc.
cariboubio.comExchange:
NASDAQ
Full time employees:
158
Industry:
Biotechnology
Sector:
Healthcare
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
2929 7th Street
Berkeley, CA 94710
Berkeley, CA 94710
CIK: 0001619856
ISIN: US1420381089
CUSIP: 142038108
